Header cover image

Swedish (OMX) Biotech Industry Analysis

UpdatedAug 07, 2024
DataAggregated Company Financials
Companies64
  • 7D-5.0%
  • 3M-0.6%
  • 1Y13.0%
  • YTD-0.6%

Over the last 7 days, the Biotech industry has dropped 5.0%, driven by Swedish Orphan Biovitrum declining 4.8%. In the past year, the industry has gained 13%. Earnings are forecast to grow by 47% annually.

Industry Valuation and Performance

Has the Swedish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 07 Aug 2024SEK 187.9bSEK 31.4b-SEK 5,419,855,742.0041.6x-34.7x6x
Fri, 05 Jul 2024SEK 192.8bSEK 30.6b-SEK 5,537,890,608.7938.6x-34.8x6.3x
Sun, 02 Jun 2024SEK 198.9bSEK 30.6b-SEK 5,722,606,652.2539.8x-34.8x6.5x
Tue, 30 Apr 2024SEK 185.1bSEK 30.8b-SEK 5,567,617,777.9350.4x-33.2x6x
Thu, 28 Mar 2024SEK 187.4bSEK 29.8b-SEK 5,637,786,411.1260x-33.2x6.3x
Sat, 24 Feb 2024SEK 179.4bSEK 29.8b-SEK 5,694,219,485.9151.4x-31.5x6x
Mon, 22 Jan 2024SEK 186.9bSEK 28.7b-SEK 1,200,602,862.0057.4x-155.6x6.5x
Wed, 20 Dec 2023SEK 179.3bSEK 28.7b-SEK 1,169,872,731.0060.2x-153.3x6.2x
Fri, 17 Nov 2023SEK 166.4bSEK 28.7b-SEK 1,231,342,852.0051.1x-135.1x5.8x
Sun, 15 Oct 2023SEK 154.5bSEK 27.4b-SEK 1,963,051,432.0048.8x-78.7x5.6x
Tue, 12 Sep 2023SEK 152.0bSEK 27.4b-SEK 1,977,389,012.0046.8x-76.9x5.6x
Thu, 10 Aug 2023SEK 157.2bSEK 27.5b-SEK 1,576,085,928.0053.6x-99.7x5.7x
Sat, 08 Jul 2023SEK 160.7bSEK 26.4b-SEK 1,314,450,404.0044.8x-122.3x6.1x
Mon, 05 Jun 2023SEK 167.9bSEK 26.4b-SEK 1,190,026,092.0045.5x-141.1x6.4x
Wed, 03 May 2023SEK 177.1bSEK 26.3b-SEK 1,249,194,561.0046.1x-141.7x6.7x
Fri, 31 Mar 2023SEK 168.0bSEK 25.4b-SEK 2,118,153,927.0041.9x-79.3x6.6x
Sun, 26 Feb 2023SEK 170.0bSEK 25.4b-SEK 2,036,417,969.0039.6x-83.5x6.7x
Tue, 24 Jan 2023SEK 177.1bSEK 23.8b-SEK 1,838,625,977.0032.3x-96.3x7.4x
Thu, 22 Dec 2022SEK 159.7bSEK 23.8b-SEK 1,838,756,322.0031.7x-86.8x6.7x
Sat, 19 Nov 2022SEK 156.9bSEK 23.9b-SEK 1,720,558,502.0032.1x-91.2x6.6x
Mon, 17 Oct 2022SEK 153.0bSEK 22.9b-SEK 3,333,771,163.0031.2x-45.9x6.7x
Wed, 14 Sep 2022SEK 158.7bSEK 22.9b-SEK 3,245,854,870.0033.9x-48.9x6.9x
Fri, 12 Aug 2022SEK 173.3bSEK 22.7b-SEK 3,505,424,214.0035.2x-49.4x7.6x
Sun, 10 Jul 2022SEK 164.2bSEK 21.4b-SEK 3,520,210,178.0040.3x-46.7x7.7x
Tue, 07 Jun 2022SEK 158.9bSEK 21.4b-SEK 3,525,315,082.0044.4x-45.1x7.4x
Thu, 05 May 2022SEK 149.3bSEK 21.3b-SEK 3,496,410,527.0045.9x-42.7x7x
Sat, 02 Apr 2022SEK 175.9bSEK 19.7b-SEK 3,159,476,364.0051.5x-55.7x8.9x
Mon, 28 Feb 2022SEK 159.5bSEK 19.6b-SEK 2,900,436,904.0049.6x-55x8.1x
Wed, 26 Jan 2022SEK 159.5bSEK 19.1b-SEK 2,049,564,151.0048.3x-77.8x8.3x
Fri, 24 Dec 2021SEK 198.8bSEK 19.1b-SEK 2,003,890,102.0052x-99.2x10.4x
Sun, 21 Nov 2021SEK 204.4bSEK 19.0b-SEK 1,490,007,893.0055.8x-137.2x10.8x
Tue, 19 Oct 2021SEK 200.6bSEK 18.1b-SEK 1,346,004,827.0047.4x-149x11.1x
Thu, 16 Sep 2021SEK 217.8bSEK 18.1b-SEK 1,339,275,285.9552.4x-162.6x12x
Sat, 14 Aug 2021SEK 193.4bSEK 18.1b-SEK 1,175,418,285.9553.6x-164.5x10.7x
Price to Earnings Ratio

-164.5x


Total Market Cap: SEK 193.4bTotal Earnings: -SEK 1,175,418,285.95Total Revenue: SEK 18.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Biotech Industry Price to Earnings3Y Average -84.8x202220232024
Current Industry PE
  • Investors are pessimistic on the Swedish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 7.3x is higher than the industry's current PS ratio of 6.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 20% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market-7.16%
Healthcare-5.25%
Biotech-4.98%
Biotech-4.98%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BIOA B BioArcticSEK 157.003.0%
+SEK 397.5m		-49.8%PS55x
DMYD B Diamyd MedicalSEK 18.069.5%
+SEK 155.6m		91.9%PS9735.1x
ISOFOL Isofol MedicalSEK 3.1037.8%
+SEK 137.3m		381.4%PB4.4x
ALZ AlzinovaSEK 3.7421.4%
+SEK 29.4m		10.0%PS9.2x
LIPUM LipumSEK 11.806.3%
+SEK 14.8m		28.8%PS4722.8x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

BONEX

SEK 264.60

Bonesupport Holding

7D

-11.0%

1Y

96.0%

PROB

SEK 243.00

Probi

7D

-12.6%

1Y

32.4%

XSPRAY

SEK 45.00

Xspray Pharma

7D

-14.3%

1Y

37.6%

DMYD B

SEK 18.06

Diamyd Medical

7D

9.5%

1Y

91.9%

BIOA B

SEK 157.00

BioArctic

7D

3.0%

1Y

-49.8%

SOBI

SEK 260.40

Swedish Orphan Biovitrum

7D

-4.8%

1Y

27.4%

ALZ

SEK 3.74

Alzinova

7D

21.4%

1Y

10.0%

BIOG B

SEK 121.80

BioGaia

7D

-4.2%

1Y

14.0%

VITR

SEK 219.40

Vitrolife

7D

-4.9%

1Y

43.6%

HNSA

SEK 37.24

Hansa Biopharma

7D

-10.2%

1Y

-22.1%

Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%

Jul 23
Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%

BIOSGN

SEK 0.64

Biosergen

7D

12.3%

1Y

-30.4%

ISOFOL

SEK 3.10

Isofol Medical

7D

37.8%

1Y

381.4%

SYNACT

SEK 8.52

SynAct Pharma

7D

0.5%

1Y

-91.4%

LIPUM

SEK 11.80

Lipum

7D

6.3%

1Y

28.8%

VICO

SEK 17.04

Vicore Pharma Holding

7D

-7.5%

1Y

-2.2%

MODTX

SEK 1.77

Modus Therapeutics Holding

7D

6.6%

1Y

-22.4%